Orchestra BioMed Stock (NASDAQ:OBIO)
Previous Close
$3.05
52W Range
$2.37 - $8.87
50D Avg
$2.97
200D Avg
$4.72
Market Cap
$124.90M
Avg Vol (3M)
$385.93K
Beta
0.63
Div Yield
-
OBIO Company Profile
Orchestra BioMed Holdings, Inc. operates as a biomedical innovation company. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension; and Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease. Its products also comprise FreeHold retractors that are minimally invasive surgical device solutions. The company has a strategic collaboration with Medtronic for the development and commercialization of BackBeat CNT for the treatment of hypertension in pacemaker-indicated patients; and a strategic partnership with Terumo Corporation for the development and commercialization of Virtue SAB for the treatment of artery disease. Orchestra BioMed Holdings, Inc. is based in New Hope, Pennsylvania.